Prothena to Report Fourth Quarter and Full Year 2016 Financial Results and Host Webcast Conference Call on February 14
(Thomson Reuters ONE) -
DUBLIN, Ireland, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein immunotherapies,
announced today that it will report its fourth quarter and full year 2016
financial results on Tuesday, February 14(th), after the close of the U.S.
financial markets. The announcement will be followed by a live audio webcast and
conference call at 4:30 PM ET.
The webcast will be made available on the Company's website
at www.prothena.com under the Investors tab in the Events and Presentations
section. Following the live audio webcast, a replay will be available on the
Company's website for at least 90 days.
To access the call via dial-in, please dial (877) 887-5215 (U.S. toll free) or
(315) 625-3069 (international) five minutes prior to the start time and refer to
conference ID number 56336849. A replay of the call will be available until
February 28, 2017 via dial-in at (855) 859-2056 (U.S. toll free) or (404)
537-3406 (international), Conference ID Number 56336849.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company
seeking to fundamentally change the course of progressive diseases with its
clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific
understanding built over decades of research in protein misfolding and cell
adhesion - the root causes of many serious or currently untreatable amyloid and
inflammatory diseases - Prothena is establishing a fully integrated research,
development and commercial focus and has advanced several drug candidates into
clinical studies while pursuing discovery of additional novel therapies. Our
pipeline of antibody-based product candidates targets a number of potential
indications including AL amyloidosis (NEOD001), Parkinson's disease and other
related synucleinopathies (PRX002), inflammatory diseases, including psoriasis
and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). For more
information, please visit the company's website at www.prothena.com.
Contacts
Investors: Tran Nguyen, CFO
650-837-8535, IR(at)prothena.com
Media: Ellen Rose, Head of Communications
650-922-2405, ellen.rose(at)prothena.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 01.02.2017 - 22:05 Uhr
Sprache: Deutsch
News-ID 521468
Anzahl Zeichen: 2942
contact information:
Town:
DUBLIN
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 166 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prothena to Report Fourth Quarter and Full Year 2016 Financial Results and Host Webcast Conference Call on February 14"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
